These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1452502)

  • 41. Pharmacokinetics and tissue penetration of cefepime.
    Nye KJ; Shi YG; Andrews JM; Wise R
    J Antimicrob Chemother; 1989 Jul; 24(1):23-8. PubMed ID: 2777727
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Effect of DQ-2556, a new cephalosporin derivative, on fecal microflora].
    Inagaki Y; Chida T; Nakaya R; Hashimoto S
    Jpn J Antibiot; 1992 Oct; 45(10):1332-41. PubMed ID: 1479685
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lack of pharmacokinetic interaction between cefepime and amikacin in humans.
    Barbhaiya RH; Knupp CA; Pfeffer M; Pittman KA
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1382-6. PubMed ID: 1510431
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of E. coli lipopolysaccharide induced fever on the plasma kinetics of cefepime in cross-bred calves.
    Pawar YG; Sharma SK
    Vet Res Commun; 2008 Feb; 32(2):123-30. PubMed ID: 17610035
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study.
    Descombes E; Martins F; Hemett OM; Erard V; Chuard C
    BMC Pharmacol Toxicol; 2016 Feb; 17():4. PubMed ID: 26846675
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of cefepime pharmacokinetics in neonatal foals and adult dogs.
    Gardner SY; Papich MG
    J Vet Pharmacol Ther; 2001 Jun; 24(3):187-92. PubMed ID: 11442796
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections.
    Vickers R; Robinson N; Best E; Echols R; Tillotson G; Wilcox M
    BMC Infect Dis; 2015 Feb; 15():91. PubMed ID: 25880933
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early clinical experience with the novel NMDA receptor antagonist CNS 5161.
    Walters MR; Bradford AP; Fischer J; Lees KR
    Br J Clin Pharmacol; 2002 Mar; 53(3):305-11. PubMed ID: 11874394
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora.
    Ritz M; Lode H; Fassbender M; Borner K; Koeppe P; Nord CE
    Antimicrob Agents Chemother; 1994 Mar; 38(3):455-9. PubMed ID: 8203837
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
    Cheatham SC; Shea KM; Healy DP; Humphrey ML; Fleming MR; Wack MF; Smith DW; Sowinski KM; Kays MB
    Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cefepime: a new fourth-generation cephalosporin.
    Okamoto MP; Nakahiro RK; Chin A; Bedikian A; Gill MA
    Am J Hosp Pharm; 1994 Feb; 51(4):463-77; quiz 541-2. PubMed ID: 8017411
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of loracarbef on the normal oropharyngeal and intestinal microflora.
    Nord CE; Grahnen A; Eckernäs SA
    Scand J Infect Dis; 1991; 23(2):255-60. PubMed ID: 1853174
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies.
    Nagy CF; Leach TS; Hoffman JH; Czech A; Carpenter SE; Guttendorf R
    Clin Ther; 2016 Sep; 38(9):2083-2097.e7. PubMed ID: 27568215
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of cefixime on the normal intestinal microflora.
    Nord CE; Movin G; Stålberg D
    Scand J Infect Dis; 1988; 20(5):547-52. PubMed ID: 3222669
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.
    Schmitt-Hoffmann A; Nyman L; Roos B; Schleimer M; Sauer J; Nashed N; Brown T; Man A; Weidekamm E
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2576-80. PubMed ID: 15215111
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of cefepime dihydrochloride arginine in subjects with renal impairment.
    Cronqvist J; Nilsson-Ehle I; Oqvist B; Norrby SR
    Antimicrob Agents Chemother; 1992 Dec; 36(12):2676-80. PubMed ID: 1482136
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The pharmacokinetics change of cefepime after Shuanghuanglian injection administration in subjects with the renal damage.
    Chen H; Min J; Li W; Zhao W; Mi S; Wang N; Zhu C
    Drug Chem Toxicol; 2016; 39(2):129-36. PubMed ID: 26108148
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiota.
    Rashid MU; Rosenborg S; Panagiotidis G; Löfdal KS; Weintraub A; Nord CE
    Int J Antimicrob Agents; 2015 Jul; 46(1):60-5. PubMed ID: 25979639
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multiple-dose pharmacokinetics of cefepime in long-term hemodialysis with high-flux membranes.
    Schmaldienst S; Traunmüller F; Burgmann H; Rosenkranz AR; Thalhammer-Scherrer R; Hörl WH; Thalhammer F
    Eur J Clin Pharmacol; 2000 Apr; 56(1):61-4. PubMed ID: 10853879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.